|SLLK, Control Peptide for TSP1 Inhibitor Catalog No.GC33329|
Sample solution is provided at 25 µL, 10mM.
GlpBio Products Cited In Reputable Papers
Sterile solutions of LSKL or SLLK peptide are made in stock solutions of 3.0 mg/mL (high dose) or 0.3 mg/mL (low dose) in sterile saline. The i.p. injection of LSKL, SLLK, or saline began 2 weeks after uninephrectomy and continues thrice weekly for 15 weeks. For the low-dosage treatment regimen, each group of 20 mice receives 3 mg/kg body weight of peptide (LSKL or SLLK) per injection or saline (100 μL/10 g body weight per injection). For the high-dosage treatment regimen, Akita mice ae given i.p. injections of LSKL or SLLK peptide at 30 mg/kg body weight per injection or saline (100 μL/10 g body weight per injection).
. Krishna SM, et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):389-98.
|Cas No.||464924-27-4||SDF||Download SDF|
|Solubility||Soluble in H2O||Storage||Store at -20°C|
|General tips||For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.|
|Shipping Condition||Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
SLLK, Control Peptide for TSP1 Inhibitor is a control peptide for LSKL (leucine-serine-lysine-leucine).
TGF-β1 is significantly lower (0.10±0.01 pg/mL) in the plasma of mice receiving LSKL compared with that in plasma of mice receiving SLLK control peptide at day 42 (0.20±0.02 pg/mL; P=0.0001). mRNA expression is assessed in the suprarenal aortic lysates obtained from mice receiving SLLK and LSKL peptides. Akita mice treated with 30 mg/kg LSKL have significantly increased nephrin expression, greater than twofold, compared with renal lysates from either saline controls or SLLK-treated mice.
. Krishna SM, et al. A peptide antagonist of thrombospondin-1 promotes abdominal aortic aneurysm progression in the angiotensin II-infused apolipoprotein-E-deficient mouse. Arterioscler Thromb Vasc Biol. 2015 Feb;35(2):389-98. . Lu A, et al. Blockade of TSP1-dependent TGF-β activity reduces renal injury and proteinuria in a murine model of diabetic nephropathy. Am J Pathol. 2011 Jun;178(6):2573-86.